About CRS

Chronic rhinosinusitis (CRS) is a debilitating disease caused by inflammation of the paranasal sinus tissues. CRS is the 5th most common chronic illness in people under age 65 in the U.S.,1 affecting approximately 31 million people or 12.5% of the adult population.2 Direct health care costs for treatment of CRS total more than $60 billion per year in the U.S.3 CRS is also highly prevalent in Europe and Asia.

There are currently no medications approved by FDA for the treatment of CRS. None of the current treatment options offer a sustained solution for CRS, including conventional steroids and sprays, as well as endoscopic sinus surgery.

Diagnosing CRS

Unmet Medical Need in CRS

With no medications currently approved by FDA for the treatment of CRS, there is a significant opportunity to improve the standard of care for the millions of patients who do not have proven adequate treatment options for this challenging disease.

Currently treatments used for CRS consist of intranasal corticosteroid sprays, oral steroids and endoscopic sinus surgery. Overall, existing medications and surgeries do not meet the medical needs for the majority of CRS patients. Due to insufficient and ineffective treatment options available to CRS patients, the market remains vastly underserved.

1 U.S. Dept of Health and Human Services https://aspe.hhs.gov/sites/default/files/pdf/75961/closerlook.pdf;

2 U.S. Centers for Disease Control and Prevention https://www.cdc.gov/nchs/fastats/sinuses.htm

3 American Academy of Asthma Allergy and Immunology https://www.aaaai.org/global/latest-research-summaries/Current-JACI-Research/chronic-rhinosinusitis-US

Back to Top